Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Iovance Biotherapeutics (IOVA) over the last 7 years, with Q3 2025 value amounting to $156.6 million.

  • Iovance Biotherapeutics' Non-cash Items rose 95085.25% to $156.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.6 million, marking a year-over-year increase of 95085.25%. This contributed to the annual value of $2.6 million for FY2024, which is 9195.58% down from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Non-cash Items stood at $156.6 million, which was up 95085.25% from $600000.0 recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Non-cash Items high stood at $156.6 million for Q3 2025, and its period low was $300000.0 during Q1 2025.
  • For the 3-year period, Iovance Biotherapeutics' Non-cash Items averaged around $24.4 million, with its median value being $11.7 million (2023).
  • Over the last 5 years, Iovance Biotherapeutics' Non-cash Items had its largest YoY gain of 95085.25% in 2025, and its largest YoY loss of 9780.04% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Non-cash Items stood at $31.7 million in 2023, then plummeted by 91.96% to $2.6 million in 2024, then soared by 6039.45% to $156.6 million in 2025.
  • Its last three reported values are $156.6 million in Q3 2025, $600000.0 for Q2 2025, and $300000.0 during Q1 2025.